Similar articles for PMID: 27635023

Year	Number of Results
1820	1
1961	1
1999	1
2002	2
2004	2
2005	4
2006	6
2008	3
2009	6
2010	5
2011	8
2012	6
2013	11
2014	6
2015	12
2016	13
2017	13
2018	3
2024	0

1

Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors.

Umlauft M, Radojewski P, Spanjol PM, Dumont R, Marincek N, Kollar A, Brunner P, Beyersmann J, Müller-Brand J, Maecke HR, Laimer M, Walter MA. Umlauft M, et al. J Nucl Med. 2017 Jan;58(1):97-102. doi: 10.2967/jnumed.116.180687. Epub 2016 Sep 15. J Nucl Med. 2017. PMID: 27635023 Free article. Clinical Trial.

2

Towards tailored radiopeptide therapy.

Radojewski P, Dumont R, Marincek N, Brunner P, Mäcke HR, Müller-Brand J, Briel M, Walter MA. Radojewski P, et al. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1231-7. doi: 10.1007/s00259-015-3030-9. Epub 2015 Mar 20. Eur J Nucl Med Mol Imaging. 2015. PMID: 25792454 Free article.

3

Effectiveness of radiolabelled somatostatin analogues (⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE) in patients with metastatic neuroendocrine tumours: a single centre experience in Mexico.

Medina-Ornelas SS, García-Pérez FO. Medina-Ornelas SS, et al. Rev Esp Med Nucl Imagen Mol. 2017 May-Jun;36(3):166-174. doi: 10.1016/j.remn.2016.09.005. Epub 2016 Nov 24. Rev Esp Med Nucl Imagen Mol. 2017. PMID: 27890514 English, Spanish.

4

Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.

Kulkarni HR, Schuchardt C, Baum RP. Kulkarni HR, et al. Recent Results Cancer Res. 2013;194:551-9. doi: 10.1007/978-3-642-27994-2_32. Recent Results Cancer Res. 2013. PMID: 22918782

5

Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland.

Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, Krogh K, Kjær A, Knigge U. Pfeifer AK, et al. Neuroendocrinology. 2011;93(3):189-96. doi: 10.1159/000324096. Epub 2011 Feb 19. Neuroendocrinology. 2011. PMID: 21335949

6

The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.

Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP. Schuchardt C, et al. Recent Results Cancer Res. 2013;194:519-36. doi: 10.1007/978-3-642-27994-2_30. Recent Results Cancer Res. 2013. PMID: 22918780

7

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP. Valkema R, et al. J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S. J Nucl Med. 2005. PMID: 15653656 Free article. Clinical Trial.

8

Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.

Marincek N, Radojewski P, Dumont RA, Brunner P, Müller-Brand J, Maecke HR, Briel M, Walter MA. Marincek N, et al. J Nucl Med. 2015 Feb;56(2):171-6. doi: 10.2967/jnumed.114.147256. Epub 2015 Jan 15. J Nucl Med. 2015. PMID: 25593116 Free article. Clinical Trial.

9

Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.

Severi S, Sansovini M, Ianniello A, Bodei L, Nicolini S, Ibrahim T, Di Iorio V, D'Errico V, Caroli P, Monti M, Paganelli G. Severi S, et al. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1955-63. doi: 10.1007/s00259-015-3105-7. Epub 2015 Jun 26. Eur J Nucl Med Mol Imaging. 2015. PMID: 26112388

10

The prognostic and predictive value of sstr₂-immunohistochemistry and sstr₂-targeted imaging in neuroendocrine tumors.

Brunner P, Jörg AC, Glatz K, Bubendorf L, Radojewski P, Umlauft M, Marincek N, Spanjol PM, Krause T, Dumont RA, Maecke HR, Müller-Brand J, Briel M, Schmitt A, Perren A, Walter MA. Brunner P, et al. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):468-475. doi: 10.1007/s00259-016-3486-2. Epub 2016 Aug 18. Eur J Nucl Med Mol Imaging. 2017. PMID: 27539020 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

92 results

Results by year